Recent developments in the field of A2A and A3 adenosine receptor antagonists.

@article{Baraldi2003RecentDI,
  title={Recent developments in the field of A2A and A3 adenosine receptor antagonists.},
  author={Pier Giovanni Baraldi and Mojgan Aghazadeh Tabrizi and Andrea Bovero and Barbara G. Avitabile and Delia Preti and Francesca Fruttarolo and Romeo Romagnoli and Katia Varani and Pier Andrea Borea},
  journal={European journal of medicinal chemistry},
  year={2003},
  volume={38 4},
  pages={
          367-82
        }
}
In the last years adenosine receptors have been extensively studied, and mainly at present we understand the importance of A(2A) and A(3) adenosine receptors. A(2A) selective adenosine receptors antagonists are promising new drugs for the treatment of Parkinson's disease, while A(3) selective adenosine receptors antagonists have been postulated as novel anti-inflammatory and antiallergic agents; recent studies also indicated a possible employment of these derivatives as antitumour agents… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS